Mixed cryoglobulinemic vasculitis is associated with the monoclonal expansion of pathognomonic B cells in chronic hepatitis C. Recently, treatment with B-cell depletion, including rituximab, a CD20 monoclonal antibody, has been successful in achieving remission from the active disease. We investigated whether B-cell depletion therapy has an impact on activation of non-B cells in the periphery. Results demonstrated that B-cell depletion therapy is associated with a statistically significant decline in activated T cells, from pretherapy to follow-up while on rituximab therapy: CD4+ 
anti-CD20 monoclonal antibody. 10, 15 Response to rituximab therapy results in a clinical response to active vasculitis indicated by a lowered
Birmingham Vasculitis Activity Score (BVAS). Rituximab has also been
shown to normalize peripheral B-and T-lymphocyte homoeostasis including improving regulation, activation, and Th1/Th2 imbalances, 16 and increase in CD4+. 17 Among healthy donors, B cells exposed to rituximab in vitro showed rapid and robust loss of measured CD19+ cells representing a loss of surface protein in a complementindependent manner. 18 In other diseases, treatment with rituximab has shown a change in both B and T cells. Patients with rheumatoid arthritis treated with rituximab showed a depletion of peripheral blood B cells through 24 weeks during a randomized-control trial; CD19+
cell first decreased and then remained stable in the control group (oral methotrexate); however, all treatment groups had an initial decrease then rebound of T cells: CD3+, CD4+ and CD8+. 19 All patients with relapsing-remitting multiple sclerosis who had lumbar puncture before and after rituximab infusion had decreased or undetectable cerebrospinal fluid (CSF) B cells, while the majority of patients had reduced CSF T cells. 20 The study objective was to determine the changes in activated and memory T cells from pretherapy to follow-up while on rituximab therapy and the correlations of these immune parameters with active disease, BVAS, among HCV-MC vasculitis patients.
| METHODS

| Study population
The study population is HCV-MC vasculitis patients treated with 
| Laboratory measurements
| Statistical analysis
We performed exploratory analysis to determine differences between the treatment and control arm for immune parameters at clinical trial baseline (pretherapy) and at the 6-month primary endpoint using Student's t-test for continuous variables. The primary analysis was to determine individual differences in immune parameters from pretherapy to the 6 and 12 months follow-up while on rituximab therapy using a paired t-test. Immune parameters (cells/μL) were expressed in means±standard deviation (SD). To determine the association of T-cell activation and remission, we determined the Pearson's correlation coefficient (R) of immune-activated T cells to both BVAS and cryoglobulin at pretherapy and during rituximab therapy. All analyses were conducted in SAS, version 9.4 (SAS Institute, Inc., Cary, NC) with a P-value<.05 (two-sided) indicating statistical significance.
| RESULTS
| Study population
The demographic and clinical characteristics of patients from the clinical trial and the results have been previously described. 10 Briefly, the rituximab treatment arm achieved a statistically significant higher remission compared to the control arm (P<.001) at the 6-month primary endpoint. 10 The 
| Decline in activated T cells with B-cell depletion therapy and remission
The mean BVAS at pretherapy was 9.4 (SD: 5.6) and significantly decreased to 2.7 (SD: 4.3) at 6-month of rituximab (P<.001). The mean cryoglobulin level at pretherapy was 10.8% of cryocrit (SD: 9.6) and significantly decreased to 6.3% of cryocrit (SD: 7.6) at 6-month of rituximab (P=.005). Table 1 shows the immune parameters that were statistically significant comparing individual differences from pretherapy to 6-months of rituximab therapy. T-cell activation was shown to decrease with therapy and BVAS for CD4+ CD38+ DR+, CD4+
CD38+ DR+, CD8+ CD38+ DR+ and CD8+ DR+ (Table 1) . Similar results for immune parameters were seen when increasing follow-up to 12 months with a significant decrease in T-cell activation with therapy and BVAS: CD4+ CD38+ DR+, CD8+ CD38, CD8+ CD38+ DR+ and CD8+ DR+ (Table 2 ).
| Correlation of activated T cells to disease state
At pretherapy, there was no significant or strong correlation between BVAS and cryoglobulin. However, at the 6-month therapy measurement, BVAS and cryoglobulin showed a significant and strong correla- 
| DISCUSSION
We demonstrated an association between T-cell activation and interactions occur in an antigen-specific manner or as part of the nonspecific inflammatory process and whether this abnormal cellular activation persists despite eradication of HCV and remission of vasculitis.
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